CVM

CEL-SCI Corporation

Investor Moves

NameValueActionChangePriceLast Price
Ken GriffinCitadel Advisors
$-62.1K
ExitQ1 2026
$62k
--
$1.22
Jim SimonsRenaissance Technologies
$115k35.9k shares
AddQ1 2026
$34k
$3.21
$1.22

Insider Trades

NameValueActionPriceLast Price
Kersten Geert RDirector, Officer: Chief Executive Officer
$360k300k shares
BuyMay 14, 2026
$1.20
$1.22
Kersten Geert RDirector, Officer: Chief Executive Officer
$119k100k shares
BuyMay 13, 2026
$1.19
$1.22
Kersten Geert RDirector, Officer: Chief Executive Officer
$200k38k shares
BuyJan 22, 2026
$5.26
$1.22
Kersten Geert RDirector, Officer: Chief Executive Officer
$50k8.4k shares
BuyDec 4, 2025
$5.96
$1.22
Watson Robert EugeneDirector
$20k2.9k shares
BuyJul 25, 2025
$6.85
$1.22
Kersten Geert RDirector, Officer: Chief Executive Officer
$200k29.2k shares
BuyJul 25, 2025
$6.85
$1.22

News

businesswire.comCEL-SCI Announces Closing of Offeringbusinesswire.comJun 16businesswire.comCEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategybusinesswire.comJun 16businesswire.comCEL-SCI Corporation Announces Pricing of Offeringbusinesswire.comJun 14businesswire.comCEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabiabusinesswire.comJun 12businesswire.comCEL-SCI Reports Fiscal Second Quarter 2026 Resultsbusinesswire.comMay 18